Company Overview and News

 
ASX rallies hard for first weekly gain in three weeks

2017-10-06 smh.com.au
The Australian market for once joined in with other global equity markets and rallied hard on Friday, with the gains helping the index mark its first positive week in three.
Upvote Downvote

 
ASX rallies hard for first weekly gain in three weeks

2017-10-06 theage.com.au
The Australian market for once joined in with other global equity markets and rallied hard on Friday, with the gains helping the index mark its first positive week in three.
Upvote Downvote

 
Brisbane City Council terminates $122 million IT contract

2017-07-28 smh.com.au
A major IT firm has threatened Brisbane CIty Council with a $50 million lawsuit after a $122 million contract was terminated after cost blow outs and lengthy delays.
Upvote Downvote

 
Technology One has 28 days to explain why council should not cancel contract

2017-05-08 smh.com.au
A technology company involved in a bitter contractual dispute with Brisbane City Council has accused the council of making incorrect information public.
Upvote Downvote

 
Why regions must be part of Brisbane's New World City mission

2017-05-01 theage.com.au
Young businessperson of the year 2016 Jock Fairweather is a man many see as the future of Brisbane's business ecosystem as it moves to become a "New World City". At 27, he calls himself "el capitano" of Little Tokyo Two, the company managing space at The Capital, a hub for startup businesses which opened early this year with the support of $5 million of ratepayers' money. In a three-part series, the city's innovation "captain" puts his thoughts on the line to explain how he thinks Southeast Queensland can be the next centre for global startup enterprise.
Upvote Downvote

 
Why regions must be part of Brisbane's New World City mission

2017-05-01 smh.com.au
Young businessperson of the year 2016 Jock Fairweather is a man many see as the future of Brisbane's business ecosystem as it moves to become a "New World City". At 27, he calls himself "el capitano" of Little Tokyo Two, the company managing space at The Capital, a hub for startup businesses which opened early this year with the support of $5 million of ratepayers' money. In a three-part series, the city's innovation "captain" puts his thoughts on the line to explain how he thinks Southeast Queensland can be the next centre for global startup enterprise.
Upvote Downvote

 
Ratepayers to foot the bill for council contract bungle

2017-03-27 smh.com.au
Brisbane ratepayers will continue to foot the bill for Brisbane City Council's IT contract blow-out with the latest expense coming in at more than $7 million.
Upvote Downvote

 
Brisbane IT firm’s $60m budget feud with Council

2017-01-30 perthnow.com.au
A BRISBANE-based IT company has accused Brisbane City Council of failing proper process when the firm was publicly lashed over a contract dispute before being notified.
Upvote Downvote

 
Joyce way off the mark on housing crisis

2017-01-25 smh.com.au
Barnaby Joyce shows, yet again, how out of touch he and the Liberal Party are with reality ("Joyce's advice for those Sydneysiders who can't afford a home", January 25). These politicians on their cushy salaries and perks have the temerity to tell us that if we can't afford a house in Sydney or Melbourne, we should either get a better job (Joe Hockey) or move out of the city (Barnaby Joyce).
Upvote Downvote

 
Brisbane City Council IT contract faces potential $60 million blow-out

2017-01-25 smh.com.au
A $122 million Brisbane City Council IT contract will be renegotiated after a systems replacement program was delayed by 18 months, with a potential cost blow-out of up to $60 million.
Upvote Downvote

 
ASX gains undermined by plunging metal prices

2016-11-16 theage.com.au
A plunge in metal prices set the scene for a flat session on the ASX, as sharp falls in the major miners were only partially offset by gains in big banks and a strong showing from energy stocks.
Upvote Downvote

 
ASX gains undermined by plunging metal prices

2016-11-16 smh.com.au
A plunge in metal prices set the scene for a flat session on the ASX, as sharp falls in the major miners were only partially offset by gains in big banks and a strong showing from energy stocks.
Upvote Downvote

 
Credit Suisse tips the new batch of market darlings

2016-11-03 theage.com.au
As investors scour the globe for growth, Australian market darlings have enjoyed unprecedented love, but Credit Suisse suggests investors are witnessing the beginning of a rotation and have offered some stocks with future darling potential. 
Upvote Downvote

 
Credit Suisse tips the new batch of market darlings

2016-11-03 smh.com.au
As investors scour the globe for growth, Australian market darlings have enjoyed unprecedented love, but Credit Suisse suggests investors are witnessing the beginning of a rotation and have offered some stocks with future darling potential. 
Upvote Downvote

 
New Jersey Health Foundation Awards $50,000 Innovation Grant to Improve Treatment for Children with Vision Dysfunction

2016-10-17 prnewswire
NEW BRUNSWICK, N.J., Oct. 17, 2016 /PRNewswire-USNewswire/ -- New Jersey Health Foundation (NJHF) has awarded a $50,000 Innovation Grant to Tara Alvarez, PhD, to help create a 3-D virtual reality therapy game for children suffering with binocular vision dysfunction, announced James M. Golubieski, president.  
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...